# MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

> **NCT02427568** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Midomafetamine HCl
- **DRUG:** Placebo
- **BEHAVIORAL:** Therapy

## Key facts

- **NCT ID:** NCT02427568
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-14
- **Primary completion:** 2017-04-25
- **Final completion:** 2018-05-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02427568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02427568, "MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02427568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*